Generic Name and Formulations:
Ketoconazole 2%; foam; contains alcohol.
Indications for EXTINA:
Topical treatment of seborrheic dermatitis in immunocompetent patients.
Apply twice daily for 4 weeks. Dispense an amount that will cover the affected area(s) into cap or other cool surface. Pick up a small amount of foam with fingertips and massage into affected area(s) until foam disappears.
Not for fungal infections. Avoid contact with eyes, mucous membranes. Product is flammable. Pregnancy (Cat.C). Nursing mothers.
Contact sensitization (eg, photoallergenicity), application site reactions (eg, burning).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma